Listen as Harold J. Burstein, MD, PhD, interviews William J. Gradishar, MD, on predicting response to breast cancer therapy.
Predictive markers, especially hormone receptors and HER2, have made an important contribution to the treatment of breast cancer by guiding physicians in selecting the most suitable therapy for individual patients.
William J. Gradishar, MD, is Professor of Medicine, Hematology/Oncology, Northwestern University, Chicago, Illinois; and Harold J. Burstein, MD, PhD, is Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. In this interview, Dr. Gradishar discusses how to select among endocrine therapies, chemotherapy regimens, and targeted treatments like trastuzumab or lapatinib based on the results of endocrine receptor testing and HER2 testing. Using these predictive markers to individualize treatment helps to achieve maximal response and progression-free survival in patients with breast cancer.
In this interview, Dr. Gradishar addresses these specific issues:
- The influence of the degree of ER and PR expression on the likelihood of response to endocrine therapy
- Comparison of qualitative and quantitative approaches to ER expression testing
- Selecting chemotherapeutic agents based on hormone receptor expression
- The influence of coexpression of ER and HER2 on choice of endocrine agent and possible use of concurrent targeted therapies
- Different methods for assessing HER2 status, including IHC, FISH, and CISH testing
- Using HER2 status to select specific chemotherapy regimens
- Topoisomerase 2 and c-myc as predictors of outcomes for treatment with anthracyclines or trastuzumab in HER2-driven tumors
- HER2 expression as a predictor for response to lapatinib therapy